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Conclusions In summary, regular ingestion of PRO did not 
reduce URS episode incidence which might be attributable 
to the low URS incidence in this study. Regular ingestion 
of PRO reduced plasma CMV and EBV antibody titres, an 
effect that can be interpreted as a benefit to overall immune 
status.
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Abbreviations
ANOVA  Analysis of variance
BMI  Body mass index
CMV  Cytomegalovirus
EBV  Epstein Barr
ELISA  Enzyme-linked immunosorbent assay
IgG  Immunoglobulin G
IPAQ  International Physical Activity Questionnaire
K3EDTA  Potassium ethylene diamine tetra acetic acid
PLA  Placebo
PRO  Probiotic
SD  Standard deviation
SEM  Standard error of mean
SIgA  Secretory immunoglobulin A
URS  Upper respiratory tract illness symptoms
Introduction
Probiotics are food supplements that contain “friendly” gut 
bacteria. There is now a reasonable body of evidence that 
regular consumption of probiotics can modify the popula-
tion of the gut microflora and influence immune function 
(Trejo and Sanz 2013).
Abstract 
Aims To assess evidence of health and immune benefit by 
consumption of a Lactobacillus casei Shirota probiotic in 
highly physically active people.
Methods Single-centre, population-based, randomized, 
double-blind, placebo-controlled trial. Daily ingestion of 
probiotic (PRO) or placebo (PLA) for 20 weeks for n = 243 
(126 PRO, 117 PLA) university athletes and games players. 
Subjects completed validated questionnaires on upper res-
piratory tract infection symptoms (URS) on a daily basis 
and on physical activity status at weekly intervals during 
the intervention period. Blood samples were collected 
before and after 20 weeks of the intervention for determi-
nation of Epstein Barr virus (EBV) and cytomegalovirus 
(CMV) serostatus and antibody levels.
Results URS episode incidence was unexpectedly low 
(mean 0.6 per individual) and was not significantly differ-
ent on PRO compared with PLA. URS episode duration 
and severity were also not influenced by PRO. A significant 
time × group interaction effect was observed for plasma 
CMV antibody titres in CMV seropositive participants 
(p < 0.01) with antibody titre falling in the PRO group 
but remaining unchanged in the PLA group over time. A 
similar effect was found for plasma EBV antibody titres in 
EBV seropositive participants (p < 0.01) with antibody titre 
falling in the PRO group but increasing in the PLA group 
over time.
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Many studies have been conducted on the effects of 
probiotic use on upper respiratory tract infection symp-
tom (URS) episodes in the general population and a recent 
systematic review (King et al. 2014) concluded that probi-
otic use resulted in fewer numbers of illness days, shorter 
illness episodes and fewer days absence from day care/
school/work. The most recent Cochrane systematic review 
of probiotic benefits for URS using data from randomised 
controlled trials involving 3720 non-athletes concluded that 
probiotics were better than placebo in reducing URS epi-
sode incidence by about 47 %, and the average duration of 
an acute URS episode by about 2 days (Hao et al. 2015).
Prolonged intense exercise has been associated with 
a transient depression of immune function (Walsh et al. 
2011a; Gleeson et al. 2013b) and a heavy schedule of 
training and competition can lead to immune impairment 
in athletes, associated with an increased susceptibility to 
upper respiratory tract infection symptoms (URS) (Walsh 
et al. 2011a; Gleeson et al. 2013a, b). Both aspects of 
innate immunity (e.g., neutrophil chemotaxis, phagocyto-
sis, degranulation and oxidative burst activity, monocyte 
toll-like receptor expression and natural killer cell cytoxic 
activity) and acquired immunity (e.g., antigen presenta-
tion by monocytes/macrophages; T lymphocyte cytokine 
production and proliferation, immunoglobulin production 
by B lymphocytes) are depressed by prolonged exercise 
(Walsh et al. 2011a; Gleeson et al. 2013b). The causes of 
immune depression after prolonged exercise are thought to 
be related to increases in circulating stress hormones (e.g., 
adrenaline and cortisol), alterations in the pro-/anti-inflam-
matory cytokine balance and increased oxidative stress. 
To date there are relatively few published studies of the 
effectiveness of probiotic use in athletes and games play-
ers; a recent comprehensive review by Pyne et al. (2015) 
identified 15 relevant experimental studies that investigated 
immunomodulatory and/or clinical outcomes. Of those 
studies that recorded URS episode incidence, five found 
reduced URS frequency or fewer days of illness (Cox et al. 
2010; Gleeson et al. 2011; West et al. 2011, 2014; Hay-
wood et al. 2014), and three reported trivial or no effects 
(Kekkonen et al. 2007; Tiollier et al. 2007; Gleeson et al. 
2012). More recently, another published study on athletes 
reported a reduction in the duration, number and severity of 
URS compared with placebo although URS episode inci-
dence was not affected (Marinkovic et al. 2016a). Studies 
that examined immunomodulatory effects of probiotics in 
athletes have reported increased interferon-γ production in 
whole blood culture (Clancy et al. 2006) and T-cells (Cox 
et al. 2010) and better maintenance of salivary SIgA during 
intensive training (Tiollier et al. 2007; Gleeson et al. 2011; 
Marinkovic et al. 2016b).
An additional measure that can be used to establish if 
regular probiotic has an impact on overall immune status 
is the change in the plasma antibody levels to the herpes 
viruses, cytomegalovirus (CMV) and Epstein Barr virus 
(EBV), from the start to the end of the study. The level 
of CMV-specific immunoglobulin G (IgG) in plasma of 
CMV seropositive individuals inversely reflects the over-
all immune system status and is part of the immune risk 
profile used to assess immune dysregulation in elderly peo-
ple (Hadrup et al. 2006; Alonso Arias et al. 2013). A recent 
double blind, placebo controlled study using a daily Lac-
tobacillus probiotic for 6 months reported that the serum 
CMV IgG titre was significantly increased at the end of 
the study in the placebo group but was unchanged in the 
probiotic group possibly because their immune system 
was able to better control viral reactivations (Moro-García 
et al. 2013). Similarly, the change in the plasma Epstein 
Barr virus (EBV)-specific immunoglobulin G (IgG) titre 
from the start to the end of the study could also be used 
to assess any change in overall immune status. Previous 
studies have established that stress-related immunosuppres-
sion can significantly increase EBV and/or CMV antibody 
titres (Glaser et al. 1985, 1999; Godbout and Glaser 2006). 
Conversely, improved cell-mediated immunity is indicated 
when an intervention causes levels of these antibodies to 
fall (Dowd et al. 2011; Moro-García et al. 2013).
Hence, the aims of the present study were to examine the 
effects of 5 months of daily oral supplementation of a fer-
mented milk drink containing the gram positive probiotic 
Lactobacillus casei Shirota, on URS episode incidence, 
the duration and severity of episodes, and plasma CMV 
and EBV antibody titres in a cohort of university-based 
endurance athletes and games players. We chose to exam-
ine this particular probiotic because it is one of the most 
popular commercially available probiotics with world-wide 
availability and there is strong evidence that the bacteria it 
contains survive gastrointestinal transit and modify the gut 
microbiota population (Matsumoto et al. 2006; Spanhaak 
et al. 1998) and can alter some aspects of systemic immu-
nity in humans (Dong et al. 2010, 2012; Matsuzaki, 1998; 
Nagao et al. 2000).
Methods
Subjects
Two hundred and sixty-eight subjects (156 males and 
112 females) who were engaged in regular sports train-
ing (predominantly endurance-based activities such as 
running, cycling, swimming, triathlon, and team games) 
volunteered to participate in the study. Subjects ranged 
from recreationally active to national level athletes and 
their self-reported training loads averaged 11 h/week. 
Subjects were required to complete a comprehensive 
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health-screening questionnaire prior to starting the study 
and had not taken any regular medication, antibiotics or 
probiotics in the 3 months prior to the study. All subjects 
were fully informed about the rationale for the study and of 
all experimental procedures to be undertaken. Subjects pro-
vided written consent to participate in the study, which had 
earlier received the approval of Loughborough University 
ethical advisory committee. Subjects were enrolled after 
having fulfilled all inclusion criteria, and presenting none 
of the exclusion criteria (determined by both questionnaire 
and interview).
Subjects could be included if they were currently 
healthy, had been involved in endurance training for at least 
2 years, engaged in at least three sessions and at least 3 h 
of total moderate/high-intensity training time per week 
and were between 18–50 years of age. Subjects represent-
ing one or more of the following criteria were excluded 
from participation: smoking or use of any medication, cur-
rently taking probiotic supplements, suffered from or had 
a history of cardiac, hepatic, renal, pulmonary neurologi-
cal, gastrointestinal, haematological or psychiatric illness; 
objected to the prescription of diet (abstinence from fer-
mented milk products other than the daily supplement).
Subjects were randomly assigned to one of two treat-
ments (probiotic or placebo) with stratification by gender 
and type of sport (A: endurance sports such as triathlon, 
swimming, cycling and distance running, n = 66; B: indi-
vidual sports such as tennis, squash and badminton, n = 33; 
C: team games such as football, rugby, hockey, lacrosse and 
basketball, n = 169). All subjects were based on campus 
except for five athletes who were from local non-university 
sports clubs. Under double-blind procedures 137 received 
the probiotic and 131 received the placebo preparation. Of 
these 268 subjects 113 (42 %) were female and 155 (58 %) 
were male. Their ages ranged from 18 to 32 with the mean 
age of the study cohort at recruitment being 21 ± 3 years 
(mean ± SD).
Study intervention
Probiotic (PRO) and placebo (PLA) supplements were sup-
plied as fermented milk in sealed pots of 65 ml with date 
stamped expiry. The PRO drink contained a minimum of 
6.5 × 109 live cells of Lactobacillus casei Shirota in each 
pot. The PLA was identical in taste and colour to the PRO 
but contained no lactobacilli. The supplements were stored 
at 3–5 °C and a fresh supply was provided by the manu-
facturer (Yakult Europe, Amsterdam, The Netherlands) 
every 2 weeks. Subjects returned to the laboratory every 
2–3 weeks to receive a fresh supply of supplement. This 
was provided in a cardboard box labelled with one of six 
letters (N, Q, R, S, T, or U). Three of these letters (N, T, U) 
corresponded to PRO and the other three (Q, R, S) to PLA 
(blinded to both the subjects and the investigators). A com-
pliance log of sample collection was taken. Subjects con-
sumed the supplement twice per day; one 65 mL pot with 
breakfast and one with the evening meal for 20 weeks. Sub-
jects were asked to keep a record of any days when they 
missed taking the supplement.
Study protocol
For the first visit to the laboratory, subjects arrived in the 
morning at 08:30–10:30 following an overnight fast of 
approximately 12 h and their body mass and height were 
recorded. Information about the study had previously been 
given to them and they signed an informed consent form. 
Subjects then sat quietly for 10 min and completed a health-
screening questionnaire and inclusion/exclusion criteria 
questionnaire. A resting venous blood sample (5 ml) was 
obtained by venepuncture from an antecubital forearm vein 
into a Vacutainer tube (Becton–Dickinson, Oxford, UK) 
containing K3EDTA. Haematological analysis was imme-
diately carried out on this sample (including haemoglo-
bin, haematocrit and total and differential leukocyte count) 
using an automated cell-counter (Ac.T™5diff haematology 
analyser, Beckman Coulter, High Wycombe, UK). Sub-
jects had to have normal haematology to be included in the 
study. The remaining blood was centrifuged for 10 min at 
5000g and 4 °C and the plasma stored at −80 °C prior to 
analysis. Subjects eligible for inclusion in the study were 
randomly assigned to the treatment or placebo group and 
asked to start taking the supplement the next day.
During the 20-week intervention period with PRO or 
PLA subjects were requested to continue with their normal 
training programs. Other supplements (Gleeson 2016) that 
might influence immune function (e.g. vitamins, miner-
als, colostrum, flavonoids) and consumption of additional 
probiotics or any fermented dairy products (e.g. yoghurt, 
sour cream, crème fraiche) were not permitted during this 
period. Subjects completed a validated URS questionnaire 
(Jackson et al. 1958) on a daily basis. Subjects were not 
required to abstain from medication when they were suf-
fering from illness symptoms but they were required, on a 
weekly basis, to report any unprescribed medications taken, 
visits to the doctor or any prescribed medications.
The illness symptoms listed on the questionnaire 
were: sneezing, headache, malaise, nasal discharge, nasal 
obstruction, sore throat, cough, ear ache, hoarseness, fever, 
chilliness and joint aches and pains. The non-numerical 
severity ratings of mild, moderate and severe of sever-
ity of symptoms were scored as 1, 2 or 3, respectively to 
provide a quantitative means of data analysis and the total 
symptom score for every subject each day was calculated 
as a sum of multiplied numbers of symptoms experienced 
by the numerical severity ratings. An URS (common cold) 
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episode was deemed present when both (1) total symptom 
score was ≥15 on any two consecutive days and (2) when 
a subject positively indicated suffering a common cold on 
≥3 days (Jackson et al. 1958). Subjects were also asked to 
rate the impact of illness symptoms on their ability to train 
(above normal, at the same level, below normal or training 
stopped). The total number of URS days was also deter-
mined as the number of days with a symptom score of ≥5 
according to Predy et al. (2005).
Subjects were also asked to fill in a standard short form 
of International Physical Activity Questionnaire (IPAQ; 
http://www.ipaq.ki.se/downloads.htm) at weekly intervals, 
thus providing a quantitative information on training loads 
in metabolic equivalents (MET)-h/week (Craig et al. 2003). 
Subjects attended the laboratory every 4 weeks for collec-
tion of fresh product and recording of body mass. In addi-
tion, venous blood samples were collected during the final 
visit.
Plasma analysis
Thawed plasma samples were analysed for CMV serosta-
tus and CMV-IgG titre by enzyme-linked immunosorbent 
assay (ELISA) (CMV IgG ELISA kit GD84, Genesis Diag-
nostics, Littleport, Cambridgeshire, UK supplied by Biohit 
Healthcare Ltd, Ellesmere Port, Cheshire, UK). Samples 
with an absorbance less than that of the 3 IU/mL standard 
were considered negative for anti-CMV IgG. In CMV sero-
positive samples, antibody titre was determined by inter-
polation from a calibration curve using standards of 0, 3, 
10 and 30 IU/mL provided with the kit. Plasma samples 
were also analysed for EBV serostatus and EBV-IgG titre 
by ELISA (Novagnost EBV-VCA IgG ELISA kit, NovaTec 
Immunodiagnostica GmbH, Dietzenbach, Germany, sup-
plied by Siemens Healthcare Diagnostics Ltd, Camberley, 
Surrey, UK). Samples with an absorbance value higher than 
15 % over the cut-off standard (10 U/mL) were considered 
positive for anti-EBV IgG. In EBV seropositive samples, 
antibody titre was determined by calculation of the increase 
above that of the cut-off standard assuming a linear calibra-
tion curve as recommended by the manufacturer.
Statistical analysis
Sample size estimation of at least 96 subjects per treat-
ment group was determined using G*Power 3.1 (Faul et al. 
2009) based on an expected rate of 2.1 ± 1.2 URS epi-
sodes (mean ± SD) during 4 winter months (Gleeson et al. 
2011), a target 20 % reduction in number of episodes (to 
1.7 ± 1.0 URS episodes), statistical power of 80 % and 
type I error of 5 %. The outcome revealed that a total of 
192 participants (per 2 arms) was required. We initially 
recruited 268 volunteers to account for an anticipated 
~30 % drop-out rate over the study period. Any difference 
in the proportion of subjects who presented with one or 
more episodes of URS during the trial between the PRO 
and PLA groups was assessed by a Chi squared test. Com-
parison between the treatments for the number of URS 
episodes was carried out using a Mann–Whitney test. For 
subjects who experienced one or more URS episodes, 
comparison between the treatments for total symptom 
severity score and the mean duration of URS episodes was 
carried out using unpaired t tests. Comparison between the 
treatments for the number of days with an URS score ≥5 
(Predy et al. 2005) was carried out using a Mann–Whit-
ney test. Changes in plasma CMV and EBV antibody titres 
in seropositive participants before and after 20 weeks 
of the treatment period were analysed using a between 
(treatment) within (time) two factor repeated measures 
ANOVA. When Mauchly’s test of sphericity was signifi-
cant, the Greenhouse-Geisser correction to the F values 
was applied. When significant main effects were found the 
Bonferroni post hoc test was applied to locate the differ-
ences. Data are presented as mean (±SEM). The accepted 
level of significance was p < 0.05.
Results
Adherence to the study
Of the 268 subjects, 137 were allocated to PRO and 131 
to PLA. There should, of course, have been equal numbers 
on PRO and PLA. We identified that during the first visit 
to the lab and treatment allocation five participants (one 
cyclist and four swimmers) were wrongly coded as indi-
vidual sports (Group B) when they should have been coded 
as endurance athletes (Group A). Retrospective analy-
sis following treatment unblinding revealed that for three 
of these participants this error made no difference to their 
treatment allocation but resulted in the two of them being 
allocated to PRO rather than PLA. A total of 243 subjects 
(126 PRO, 117 PLA) completed the full 20 weeks of the 
study and the proportion of males (0.58) was the same in 
both PRO and PLA groups. The number of dropouts was 
smaller than anticipated and there were slightly fewer 
(n = 11) dropouts on PRO than on PLA (n = 14). Reasons 
for dropout included going abroad on vacation during the 
Christmas period (n = 1), leaving the university (n = 5), 
injury (n = 4), persistent non-respiratory illness preventing 
them from performing training (n = 2), disliking the prod-
uct (n = 5) or due to undisclosed reasons (n = 8).
Adherence to the intervention was good: subjects who 
completed the study reported that they missed taking the 
supplement on average only on 4 days. Blood samples were 
obtained pre- and post-intervention from 223 subjects.
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Patterns in baseline characteristics
Baseline characteristics of the subjects who completed the 
study, including body mass, height, body mass index (BMI) 
and self-reported weekly training duration for the PRO 
and PLA groups are shown in Table 1. The baseline val-
ues were similar with no statistically significant difference 
between the two treatment groups. By the end of the study 
body mass had increased by 0.7 ± 0.2 kg (p < 0.001) with 
the increase for participants on PRO (0.9 ± 0.2 kg) being 
slightly higher but not significantly different (p = 0.564) 
than that for PLA (0.5 ± 0.2 kg).
Physical activity levels
Analysis of the IPAQ questionnaires indicated that the 
training loads were not consistent over the 20 weeks of the 
study as illustrated in Fig. 1. The training loads decreased 
significantly in time (p = 0.001) from week 4 until week 
10 after which the level returned to starting levels. In this 
~20 % reduction in physical activity there was no sta-
tistical difference between the PRO and the PLA group 
(p = 0.709).
The period of reduced physical activity corresponded 
to the Christmas vacation and exam period during 
December–January.
Over the 20-week study period mean training loads were 
not different for the PRO and PLA groups: 79.4 (2.9) and 
82.1 (3.2) MET-h/week, respectively (p = 0.545). This is 
equivalent to about 13 (1) hours of moderate-vigorous 
activity per week.
URS incidence
133 subjects did not experience a single URS episode dur-
ing the study period whereas 110 subjects experienced at 
least one URS episode during the study period. Within the 
whole subject cohort there was a rising incidence of infec-
tion during weeks 4–6, 9–11 and 13–17 (Fig. 2).
The proportion of subjects from the PLA group who 
experienced one or more URS episodes was 0.42 (i.e. 42 % 
of subjects in the group) whereas the proportion from the 
PRO group was 0.48. The difference in proportions was not 
significant (Chi squared test statistic = 0.820, p = 0.365). 
On average, subjects experienced their first URS episode in 
week 8 for both PRO and PLA groups.
The number of URS episodes, number of days with URS 
score ≥5 and mean total symptom score and duration of 
URS episodes were not different between PRO and PLA 
(Table 2). The proportion of subjects whose training was 
negatively affected when URS was present was not differ-
ent between PRO and PLA (0.33 for both; Chi squared test 
statistic = 0.000, p = 1.000).
Table 1  Baseline characteristics of the subjects who completed the 
study
Values are expressed as mean ± SEM. No significant differences 
between PRO and PLA
M males, F females, A endurance sports, B individual sports, C games 
players
Probiotic Placebo
Number (M, F) 126 (73, 53) 117 (69, 48)
Sport (A, B, C) 33, 16, 77 31, 14, 72
Age (years) 20.3 ± 0.2 20.6 ± 0.2
Body mass (kg) 72.3 ± 1.1 73.3 ± 1.0
Height (cm) 176.0 ± 0.9 176.6 ± 0.9
BMI (kg/m2) 23.2 ± 0.2 23.4 ± 0.2
Training (h/week) 11 ± 1 11 ± 1
Fig. 1  Training loads in 
MET-h/week over the 20-week 
study period for subjects who 
completed the study. PLA repre-
sented by open square symbols; 
PRO represented by closed 
diamond symbols. Data are 
mean and SEM. No difference 
between treatments. Signifi-
cantly different from week 1: 
*p < 0.05, **p < 0.01
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During weeks when an URS episode was present, the 
proportion of subjects who took medication was similar 
in the PRO and PLA groups (0.30 and 0.33, respectively; 
Chi squared test = 0.219, p = 0.640) and the proportion 
who went to see their doctor was also similar in the PRO 
and PLA groups (0.04 and 0.02, respectively; Chi squared 
test = 0.602, p = 0.438).
Blood leukocyte counts
There were no significant differences either before or 
after the 20-week supplementation period between PLA 
and PRO in blood total or differential leukocyte counts 
(Table 3).
Plasma herpesvirus antibody titres
In the PLA group 25 % of subjects were CMV seropositive 
at the start of the study and 23 % in the PRO group. At the 
end of the study a further 2 and 3 participants had become 
Fig. 2  Percentage of the cohort 
reporting an URS episode for 
each week of the study period
Table 2  Number of URS episodes, number of days with URS symp-
tom score ≥5, and mean total symptom score and duration for URS 
episodes in the 20-week period (per person)
Values are expressed as mean ± SEM
PRO PLA p
URS episodes 0.7 ± 0.1 0.6 ± 0.1 0.417
# Days with score ≥5 8 ± 1 8 ± 1 0.404
Total symptom score 62 ± 5 64 ± 6 0.312
URS episode duration 5.6 ± 0.4 5.9 ± 0.5 0.713
Table 3  Total and differential 
blood leukocyte counts 
(cells × 109/L) before and after 
20 weeks of the intervention 
period
Values are expressed as mean ± SEM
Before 20 weeks p (PLA vs PRO:  
before, after 20 weeks)
Total Leukocytes
 PLA 6.17 ± 0.13 5.72 ± 0.11 0.401, 0.260
 PRO 6.18 ± 0.13 5.85 ± 0.13
Neutrophils
 PLA 3.30 ± 0.10 2.91 ± 0.11 0.789, 0.391
 PRO 3.34 ± 0.12 3.06 ± 0.13
Monocytes
 PLA 0.60 ± 0.02 0.58 ± 0.02 0.671, 0.997
 PRO 0.61 ± 0.02 0.58 ± 0.01
Lymphocytes
 PLA 1.98 ± 0.05 1.95 ± 0.05 0.134, 0.110
 PRO 2.13 ± 0.05 2.06 ± 0.04
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CMV seropositive in the PLA and PRO groups, respec-
tively. A significant main effect of time (p = 0.023) and a 
significant time × group interaction effect (p = 0.003) was 
observed for plasma CMV IgG titres in CMV seropositive 
participants with antibody titre falling in the PRO group but 
remaining unchanged in the PLA group over time (Fig. 3).
In the PLA group 67 % of subjects were EBV seroposi-
tive at the start of the study and 77 % in the PRO group. 
At the end of the study a further 6 and 3 participants had 
become EBV seropositive in the PLA and PRO groups, 
respectively. At the start of the study the EBV antibody titre 
was not significantly different in the PLA and PRO groups. 
A significant time × group interaction effect (p = 0.001) 
was observed for plasma EBV IgG titres in EBV sero-
positive participants with antibody titre falling in the PRO 
group but increasing in the PLA group over time (Fig. 4). 
Despite these significant interaction effects, herpesvirus 
antibody titres were not significantly different between 
PRO and PLA groups at the end of the study.
Blinding
Of the 243 subjects who completed the study, 75 indicated 
that they had no idea which treatment they were on. Of the 
168 subjects who expressed an opinion, 93 (55 %) were 
correct and 45 % were incorrect in their selection of treat-
ment; hence, the study blinding was effective.
Discussion
The present study investigated the effects of regular probi-
otic intake on self-reported URS in a group of highly active 
individuals engaged in their normal level of training and 
competition during the period October 2014 to March 2015. 
The main findings of the present study were that 20 weeks 
of daily probiotic supplementation did not reduce incidence 
of URS episodes or the number of days with a symptom 
score ≥5. There was also no difference between PRO and 
PLA in the proportion of subjects who experienced at least 
one URS episode. Similarly, in those who experienced one 
or more URS episodes, the duration and severity of the epi-
sodes were not different between PRO and PLA. However, 
regular ingestion of probiotic reduced the CMV and EBV 
antibody titres in seropositive participants.
The individuals recruited to this study were highly-trained, 
competitive athletes undertaking daily exercise and simi-
lar cohorts engaged in similar volumes of training have been 
shown to be at a higher risk of URS when exposed to patho-
gens (Gleeson et al. 2013a, b; Nieman et al. 1990). However, 
the mean number of URS episodes in the study cohort (0.6) 
was considerably lower than that expected based on the results 
of our previous smaller scale study (Gleeson et al. 2011) 
where it was 2.1 in the PLA group. The much lower rate of 
common cold incidence than anticipated among the athlete 
cohort examined in our present study may have prevented us 
from detecting a significant effect of probiotic supplementa-
tion on respiratory infection incidence. Essentially, our study 
was underpowered and the outcome is therefore not repre-
sentative for the potential efficacy of the probiotic product. 
There are several possible reasons for the lower than expected 
URS incidence. Firstly, common cold and influenza incidence 
among the general population in the UK during the winter of 
2014–2015 (Public Health England National Weekly Influ-
enza Report 2015) was relatively low compared with the three 
previous years. Secondly, more guidelines for athletes on how 
Fig. 3  Plasma CMV IgG antibody titre in the PRO and PLA groups 
at the start and end of the study. Significant main effect of time 
(p = 0.023) and significant time × group interaction (p = 0.023). 
Significantly different from week 0 in PRO group only: **p < 0.01
Fig. 4  Plasma EBV IgG antibody titre in the PRO and PLA groups 
at the start and end of the study. Significant time × group interac-
tion (p = 0.001). Significantly different from week 0: **p < 0.01 with 
decrease in PRO group and increase in PLA group
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to avoid infection are available in the public domain including 
review articles (e.g. Walsh et al. 2011b; Gleeson and Walsh 
2012), websites (e.g. British Association of Sport and Exercise 
Sciences, English Institute of Sport), media, press and maga-
zines (e.g. Runners’ World, Cycling Weekly). Thus, certainly 
in the UK, there is a diminishing population of illness prone 
athletes who are not aware of these countermeasures.
Despite the absence of any effect of probiotic on URS in 
the present study, there was a significant impact on overall 
immune status as indicated by the differences in the changes 
in the plasma CMV-specific and EBV-specific IgG titres on 
PRO and PLA from the start to the end of the study. The 
level of the CMV antibody in plasma of CMV seropositive 
individuals inversely reflects the overall immune system 
status and is part of the immune risk profile used to assess 
immune dysregulation in elderly people (Hadrup et al. 
2006; Alonso Arias et al. 2013). Among young adult ath-
letes in a previous study (He et al. 2013) 25 % of individu-
als were CMV seropositive and this was confirmed in the 
present study. Among elderly people the proportion of CMV 
seropositive individuals will be much higher [approx. 90 % 
in the over 60 s (Dowd et al. 2011)] and a recent double 
blind, placebo controlled study of elderly volunteers using 
a daily Lactobacillus probiotic for 6 months reported that 
the serum CMV IgG titre was significantly increased at the 
end of the study in the placebo group but was unchanged in 
the probiotic group possibly because their immune system 
was able to better control viral reactivations (Moro-García 
et al. 2013). In the present study Lactobacillus casei Shi-
rota ingestion significantly reduced the CMV antibody titre 
in CMV seropositive participants with no change in the pla-
cebo group. The percentage of individuals seropositive for 
EBV (72 %) was substantially higher than for CMV (24 %) 
in our cohort of student athletes as previously reported by 
He et al. (2013). In the present study, similar to the findings 
for CMV, Lactobacillus casei Shirota ingestion significantly 
reduced the EBV antibody titre in EBV seropositive partici-
pants whereas there was a significant increase in the placebo 
group. These reductions in herpesvirus antibody titres with 
regular probiotic ingestion can be interpreted as indicating 
an overall benefit to immune system status. Such effects are 
desirable for long-term health as studies have shown that 
poor control of herpes virus reactivation may contribute to 
naïve T cell exhaustion and earlier onset of immunosenes-
cence (Simpson et al. 2016). The present study does not pro-
vide any evidence of the mechanism(s) whereby herpesvirus 
antibody titres are reduced by the probiotic but modulation 
of host immunity is an important potential mechanism by 
which probiotics confer health benefits (Trejo and Sanz 
2013). Studies by Dong et al. (2010, 2012) have established 
that Lactobacillus casei Shirota promotes natural killer 
cell activity, activates cytotoxic lymphocytes and increases 
T helper 1 cytokine production which could potentiate the 
destruction of virus-infected cells in the body, reducing viral 
replication and subsequent antiviral antibody production.
In summary, 20 weeks of daily Lactobacillus casei Shi-
rota probiotic supplementation did not reduce URS epi-
sode incidence, duration or severity in a group of highly 
active individuals engaged in their normal level of training 
and competition over the winter months. However, regular 
ingestion of this probiotic reduced plasma CMV and EBV 
antibody titres, an effect that can be interpreted as a benefit 
to overall immune status.
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